Protara Therapeutics
TARA
60 hedge funds and large institutions have $157M invested in Protara Therapeutics in 2024 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 15 increasing their positions, 10 reducing their positions, and 5 closing their positions.
719% more capital invested
Capital invested by funds: $19.1M → $157M (+$137M)
500% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 5
71% more funds holding
Funds holding: 35 → 60 (+25)
50% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 10
35.81% more ownership
Funds ownership: 50.64% → 86.45% (+36%)
72% less call options, than puts
Call options by funds: $345K | Put options by funds: $1.24M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$7.34M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.27M |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$6.75M |
| 4 |
Blackstone Inc
New York
|
+$5.43M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$4.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Stempoint Capital
New York
|
-$1.97M |
| 2 |
Renaissance Technologies
New York
|
-$628K |
| 3 |
Two Sigma Investments
New York
|
-$554K |
| 4 |
Two Sigma Advisers
New York
|
-$277K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$142K |
TARA Hedge Fund Activity: Q4 2024 in Review
60 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q4 2024, worth a combined $157M — up 719% from $19.1M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new TARA positions and 5 closed out — a net gain of 25 holders — while 15 added to existing stakes and 10 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $7.34M. The largest seller was Stempoint Capital, cutting an estimated $1.97M.
- 60 institutional investors held Protara Therapeutics (TARA) as of Q4 2024, up from 35 in Q3 2024.
- Funds reported $157M of Protara Therapeutics stock for Q4 2024, up 719% quarter-over-quarter.
- 30 funds opened new Protara Therapeutics positions in Q4 2024 and 5 closed out, a net change of +25 holders.
- The largest Protara Therapeutics buyer in Q4 2024 was Janus Henderson Group, an estimated $7.34M added.
- The largest Protara Therapeutics seller in Q4 2024 was Stempoint Capital, an estimated $1.97M sold.
Based on aggregated 13F filings for Q4 2024.